COHANCE

Cohance Lifesciences Limited

Global CDMO offering integrated development and manufacturing solutions

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

cohance.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹464.05
Market cap
17,766 Cr
Stock P/E
167.2
P/B
4.55
Dividend yield
1.1%
ROE (FY26)
4.4%
ROCE (FY26)
5.8%
Operating margin (FY26)
10.6%
Debt / equity (FY26)
0.04
OCF / EBITDA (FY26)
86.3%
OCF / EBITDA (3Y)
84.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Cohance Lifesciences develops and manufactures drug molecules, intermediates and specialty chemicals on contract for global pharmaceutical and crop-science innovators, and also sells its own active pharmaceutical ingredients (APIs) and formulations.

Company snapshot

29thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.04x — the company is largely funded by its own money, not borrowed funds.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales231 Cr220 Cr253 Cr231 Cr258 Cr307 Cr402 Cr549 Cr556 Cr545 Cr619 Cr422 Cr
Operating expenses (approx.)133 Cr155 Cr180 Cr151 Cr154 Cr189 Cr328 Cr437 Cr435 Cr449 Cr520 Cr421 Cr
EBITDA98 Cr65 Cr73 Cr80 Cr104 Cr118 Cr74 Cr112 Cr121 Cr95 Cr99 Cr1 Cr
OPM %42.4%29.6%29.0%34.6%40.4%38.3%18.3%20.4%21.8%17.5%15.9%0.3%
Other income20 Cr14 Cr17 Cr18 Cr14 Cr16 Cr11 Cr14 Cr16 Cr6 Cr-2 Cr12 Cr
Interest0.50 Cr1 Cr2 Cr2 Cr2 Cr3 Cr6 Cr10 Cr9 Cr9 Cr9 Cr7 Cr
Depreciation12 Cr13 Cr17 Cr13 Cr17 Cr20 Cr27 Cr45 Cr44 Cr47 Cr51 Cr50 Cr
Profit before tax105 Cr65 Cr71 Cr83 Cr100 Cr110 Cr52 Cr63 Cr84 Cr41 Cr20 Cr-43 Cr
Tax %24.5%28.6%24.7%26.9%17.6%24.1%24.9%26.1%20.7%28.5%58.3%-5.4%
Net profit80 Cr47 Cr53 Cr61 Cr82 Cr83 Cr39 Cr46 Cr66 Cr29 Cr8 Cr-45 Cr
EPS (₹)₹3.13₹1.84₹2.10₹2.39₹3.23₹3.26₹1.65₹1.28₹1.94₹0.96₹0.51₹-0.63

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales378 Cr834 Cr1,010 Cr1,320 Cr1,340 Cr1,051 Cr1,198 Cr2,269 CrSign in free for the trailing twelve months
Operating expenses (approx.)206 Cr449 Cr569 Cr741 Cr774 Cr646 Cr822 Cr1,842 CrSign in free for the trailing twelve months
EBITDA172 Cr385 Cr440 Cr579 Cr567 Cr406 Cr375 Cr427 CrSign in free for the trailing twelve months
OPM %45.4%46.2%43.6%43.9%42.3%38.6%31.3%18.8%Sign in free for the trailing twelve months
Other income0.60 Cr18 Cr14 Cr92 Cr46 Cr62 Cr59 Cr34 CrSign in free for the trailing twelve months
Interest3 Cr23 Cr9 Cr6 Cr5 Cr7 Cr12 Cr37 CrSign in free for the trailing twelve months
Depreciation11 Cr24 Cr32 Cr39 Cr48 Cr55 Cr77 Cr187 CrSign in free for the trailing twelve months
Profit before tax158 Cr405 Cr468 Cr668 Cr560 Cr406 Cr344 Cr207 CrSign in free for the trailing twelve months
Tax %30.8%21.6%22.5%32.0%26.5%26.0%23.0%27.5%Sign in free for the trailing twelve months
Net profit109 Cr317 Cr362 Cr454 Cr411 Cr300 Cr265 Cr150 CrSign in free for the trailing twelve months
EPS (₹)₹8.59₹24.91₹14.23₹17.83₹16.16₹11.80₹10.52₹4.69Sign in free for the trailing twelve months
Dividend payout %——7.0%22.4%49.5%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital13 Cr13 Cr25 Cr25 Cr25 Cr25 Cr25 Cr38 Cr
Reserves578 Cr832 Cr1,155 Cr1,502 Cr1,710 Cr2,025 Cr1,671 Cr3,873 Cr
Borrowings83 Cr186 Cr141 Cr96 Cr69 Cr39 Cr78 Cr170 Cr
Other liabilities110 Cr142 Cr152 Cr207 Cr161 Cr165 Cr1,113 Cr1,526 Cr
Total liabilities783 Cr1,173 Cr1,474 Cr1,830 Cr1,966 Cr2,254 Cr3,032 Cr5,730 Cr
Fixed assets (net)268 Cr353 Cr437 Cr531 Cr584 Cr567 Cr995 Cr1,990 Cr
CWIP111 Cr102 Cr96 Cr30 Cr165 Cr179 Cr255 Cr173 Cr
Investments7 Cr338 Cr542 Cr598 Cr536 Cr904 Cr337 Cr529 Cr
Loans & advances—0.20 Cr0.22 Cr0.19 Cr0.19 Cr0.83 Cr0.39 Cr8 Cr
Inventories157 Cr175 Cr201 Cr283 Cr313 Cr231 Cr167 Cr562 Cr
Trade receivables148 Cr117 Cr102 Cr236 Cr111 Cr134 Cr284 Cr681 Cr
Cash & bank11 Cr12 Cr7 Cr45 Cr65 Cr47 Cr85 Cr49 Cr
Other assets81 Cr76 Cr89 Cr106 Cr192 Cr191 Cr908 Cr1,737 Cr
Total assets783 Cr1,173 Cr1,474 Cr1,830 Cr1,966 Cr2,254 Cr3,032 Cr5,730 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity50 Cr416 Cr383 Cr330 Cr451 Cr358 Cr288 Cr368 Cr
Cash from investing-65 Cr-422 Cr-311 Cr-136 Cr-195 Cr-362 Cr-255 Cr-255 Cr
Cash from financing26 Cr6 Cr-77 Cr-156 Cr-236 Cr-14 Cr3 Cr-165 Cr
Net cash flow11 Cr0.79 Cr-5 Cr37 Cr20 Cr-18 Cr38 Cr-48 Cr
Free cash flow (OCF − Capex)-6 Cr317 Cr273 Cr255 Cr165 Cr307 Cr132 Cr148 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %23.9%41.5%36.1%41.5%31.3%19.8%18.6%5.8%
ROE %18.5%37.5%30.7%29.7%23.7%14.6%14.6%4.4%
Debtor days142513765304686109
Inventory days459266236225265317272290
Days payable15710897845558131147
Cash conversion cycle445209175206240306228253
OCF / EBITDA %29.4%108.0%87.0%57.0%79.6%88.3%76.8%86.3%
OCF / EBITDA % (3 years)——85.2%80.4%73.4%73.4%81.4%84.0%
Debt / equity0.140.220.120.060.040.020.050.04
Current ratio2.471.952.575.366.3711.822.342.78
Net debt / EBITDA0.420.450.300.090.0077-0.02-0.020.28